How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping

Pharmacogenomics

Volumn 15, Issue 5, 2014, Pages 655-665

  Verbeurgt, Paul ^a   Mamiya, Tyler ^a   Oesterheld, Jessica ^a  

^a Genelex Corporation   (United States)

Author keywords

CYP2C19; CYP2C9; CYP2D6; CYP450; cytochrome; drug interactions; drug drug; drug gene; personalized medicine; pharmacogenomics; polymorphism

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HYDROCODONE; METOPROLOL; SIMVASTATIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6;

ADULT; AGED; ALLELE; ARTICLE; CHEMICAL INTERACTION; CONTROLLED STUDY; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; DRUG DRUG GENE INTERACTION; DRUG DRUG INTERACTION; DRUG GENE INTERACTION; GENE; GENE INTERACTION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PILOT STUDY; RETROSPECTIVE STUDY; VERY ELDERLY; ADOLESCENT; ALGORITHM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENE FREQUENCY; GENETICS; MALE; MIDDLE AGED; PHARMACIST; PREVALENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 CYP2D6; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACISTS; PREVALENCE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84899867599     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.6     Document Type: Article

References (37)

1. WHO. International drug monitoring: The role of national centres. Report of a WHO meeting. World Health Organ. Tech. Rep. Ser. 498, 1-25 (1972).
2. FDA. Safe use initiative: Collaborating to reduce preventable harm from medications (2009). www.fda.gov/downloads/drugs/drugsafety/ucm188961.pdf
3. Centers for Disease Control and Prevention: Medication Safety Programme (2010). www.cdc.gov/medicationsafety/basics.html
4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-Analysis of prospective studies. JAMA 279(15), 1200-1205 (1998).
5. Giacomini KM, Krauss RM, Roden DM, Eichelbaum M, Hayden MR, Nakamura Y. When good drugs go bad. Nature 446(7139), 975-977 (2007).
6. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA 286(18), 2270-2279 (2001).
7. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future. Trends Pharmacol. Sci. 25(4), 193-200 (2004).
8. Hisaka A, Ohno Y, Yamamoto T, Suzuki H. Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacol. Ther. 125(2), 230-248 (2010).
9. Sanchez Munoz-Torrero JF, Barquilla P, Velasco R. et al. Adverse drug reactions in internal medicine units and associated risk factors. Eur. J. Clin. Pharmacol. 66(12), 1257-1264 (2010).
10. Tulner LR, Frankfort SV, Gijsen GJ, Van Campen JP, Koks CH, Beijnen JH. Drug-drug interactions in a geriatric outpatient cohort: Prevalence and relevance. Drugs Aging 25(4), 343-355 (2008).
11. Marzolini C, Elzi L, Gibbons S. et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort study. Antivir. Ther. 15(3), 413-423 (2010).
12. Smithburger PL, Kane-Gill SL, Seybert AL Drug-drug interactions in cardiac and cardiothoracic intensive care units: An analysis of patients in an academic medical centre in the US. Drug Saf. 33(10), 879-888 (2010).
13. Mino-Leon D, Galvan-Plata ME, Doubova SV, Flores-Hernandez S, Reyes-Morales H. A pharmacoepidemiological study of potential drug interactions and their determinant factors in hospitalized patients. Rev. Invest. Clin. 63(2), 170-178 (2011).
14. Lamy PP. The elderly and drug interactions. J. Am. Geriatr. Soc. 34(8), 586-592 (1986).
15. Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin. Drug Saf. 11(1), 83-94 (2012).
16. Glintborg B, Andersen S, Dalhoff K. Drug-drug interactions among recently hospitalised patients-frequent but mostly clinically insignificant. Eur. J. Clin. Pharmacol. 61(9), 675-681 (2005).
17. Obreli-Neto PR, Nobili A, De Oliveira Baldoni A. et al. Adverse drug reactions caused by drug-drug interactions in elderly outpatients: A prospective cohort study. Eur. J. Clin. Pharmacol. 68(12), 1667-1676 (2012).
18. Kurfees JF, Dotson RL. Drug interactions in the elderly. J. Fam. Pract. 25(5), 477-488 (1987).
19. Tamai I, Strome L, Marshall C, Mooradian A. Analysis of drug-drug interactions among nursing home residents. Am. J. Hosp. Pharm. 46(8), 1567-1569 (1989).
20. Kohler GI, Bode-Boger SM, Busse R, Hoopmann M, Welte T, Boger RH. Drug-drug interactions in medical patients: Effects of in-hospital treatment and relation to multiple drug use. Int. J. Clin. Pharmacol. Ther. 38(11), 504-513 (2000).
21. Karczewski KJ, Daneshjou R, Altman RB. Chapter 7: Pharmacogenomics. In: PLoS Comput. Biol. Lewitter F, Kann M (Eds) (2012).
22. Conrado DJ, Rogers HL, Zineh I, Pacanowski MA. Consistency of drug-drug and gene-drug interaction information in US FDA-Approved drug labels. Pharmacogenomics 14(2), 215-223 (2013).
23. Peterson JF, Bowton E, Field JR. et al. Electronic health record design and implementation for pharmacogenomics: A local perspective. Genet. Med. Official J. Am. Coll. Med. Genet. 15(10), 833-841 (2013).
24. Tod M, Nkoud-Mongo C, Gueyffier F. Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: A general approach. AAPS J. 15(4), 1242-1252 (2013).
25. Kubica A, Kozinski M, Grzesk G, Fabiszak T, Navarese E, Goch A. Genetic determinants of platelet response to clopidogrel. J. Thromb. Thrombolysis 32(4), 459-466 (2011).
26. Bjorkman IK, Fastbom J, Schmidt IK, Bernsten CB. Pharmaceutical care of the elderly in europe research G: Drug-drug interactions in the elderly. Ann. Pharmacother. 36(11), 1675-1681 (2002).
27. Kisor DF, Munro C, Loudermilk E. Pharmacogenomics and the most commonly prescribed drugs of 2011. Pharm. Times (2012). www.pharmacytimes.com/ publications/issue/2012/December2012/Pharmacogenomics-And-The-Most-Commonly- Prescribed-Drugs-of-2011
28. Mikus G, Schowel V, Drzewinska M. et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin. Pharmacol. Ther. 80(2), 126-135 (2006).
29. Gschwind L, Rollason V, Boehlen F. et al. Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment. Pharmacogenomics 14(7), 745-753 (2013).
30. Sim SC. The human cytochrome P450 (CYP) allele nomenclature database (2013). www.cypalleles.ki.se
31. Patterson R, Oesterheld JO. Genetic data analysis and database tools. US Patent #US8311851 (2012). www.google.com/patents/US8311851
32. Patterson R, Oesterheld JO. Genetic data analysis and database tools. US patent #US8099298 (2012). www.google.com/patents/US8311851
33. Villagra D, Goethe J, Schwartz HI. et al. Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes. Biomarkers 5(4), 427-438 (2011).
34. Zakrzewski-Jakubiak H, Doan J, Lamoureux P, Singh D, Turgeon J, Tannenbaum C. Detection and prevention of drug-drug interactions in the hospitalized elderly: Utility of new cytochrome P450-based software. Am. J. Geriatr. Pharmacother. 9(6), 461-470 (2011).
35. Hoffmann W, Van Den Berg N, Thyrian JR, Fiss T. Frequency and determinants of potential drug-drug interactions in an elderly population receiving regular home visits by GPs-results of the home medication review in the AGnES-studies. Pharmacoepidemiol. Drug Saf. 20(12), 1311-1318 (2011).
36. Lin CF, Wang CY, Bai CH. Polypharmacy, aging and potential drug-drug interactions in outpatients in Taiwan: A retrospective computerized screening study. Drugs Aging 28(3), 219-225 (2011).
37. Heuberger R. Polypharmacy and food-drug interactions among older persons: A review. J. Nutr. Gerontol. Geriatr. 31(4), 325-403 (2012).